PURPOSE: The combination of chemotherapy and immunotherapy has not been examined in patients with advanced pancreatic cancer. We conducted a study of two granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines (CG8020/CG2505) as immunotherapy administered alone or in sequence with cyclophosphamide in patients with advanced pancreatic cancer. EXPERIMENTAL DESIGN: This was an open-label study with two cohorts: cohort A, 30 patients administered a maximum of six doses of CG8020/CG2505 at 21-day intervals; and cohort B, 20 patients administered 250 mg/m(2) of cyclophosphamide i.v. 1 day before the same immunotherapy given as in cohort A. The primary objective was to evaluate safety and duration of immunity. Secondary objectives included time to disease progression and median overall survival. RESULTS: The administration of CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity. Median survival values in cohort A and cohort B were 2.3 and 4.3 months, respectively. CD8(+) T-cell responses to HLA class I-restricted mesothelin epitopes were identified predominantly in patients treated with cyclophosphamide + CG8020/CG2505 immunotherapy. CONCLUSION: Granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity in patients with advanced pancreatic cancer. Also, mesothelin-specific T-cell responses were detected/enhanced in some patients treated with CG8020/CG2505 immunotherapy. In addition, cyclophosphamide-modulated immunotherapy resulted in median survival in a gemcitabine-resistant population similar to chemotherapy alone. These findings support additional investigation of cyclophosphamide with CG8020/CG2505 immunotherapy in patients with advanced pancreatic cancer.
PURPOSE: The combination of chemotherapy and immunotherapy has not been examined in patients with advanced pancreatic cancer. We conducted a study of two granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines (CG8020/CG2505) as immunotherapy administered alone or in sequence with cyclophosphamide in patients with advanced pancreatic cancer. EXPERIMENTAL DESIGN: This was an open-label study with two cohorts: cohort A, 30 patients administered a maximum of six doses of CG8020/CG2505 at 21-day intervals; and cohort B, 20 patients administered 250 mg/m(2) of cyclophosphamide i.v. 1 day before the same immunotherapy given as in cohort A. The primary objective was to evaluate safety and duration of immunity. Secondary objectives included time to disease progression and median overall survival. RESULTS: The administration of CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity. Median survival values in cohort A and cohort B were 2.3 and 4.3 months, respectively. CD8(+) T-cell responses to HLA class I-restricted mesothelin epitopes were identified predominantly in patients treated with cyclophosphamide + CG8020/CG2505 immunotherapy. CONCLUSION:Granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity in patients with advanced pancreatic cancer. Also, mesothelin-specific T-cell responses were detected/enhanced in some patients treated with CG8020/CG2505 immunotherapy. In addition, cyclophosphamide-modulated immunotherapy resulted in median survival in a gemcitabine-resistant population similar to chemotherapy alone. These findings support additional investigation of cyclophosphamide with CG8020/CG2505 immunotherapy in patients with advanced pancreatic cancer.
Authors: P Kozuch; M L Grossbard; A Barzdins; M Araneo; A Robin; D Frager; P Homel; J Marino; P DeGregorio; H W Bruckner Journal: Oncologist Date: 2001
Authors: E M Jaffee; R H Hruban; B Biedrzycki; D Laheru; K Schepers; P R Sauter; M Goemann; J Coleman; L Grochow; R C Donehower; K D Lillemoe; S O'Reilly; R A Abrams; D M Pardoll; J L Cameron; C J Yeo Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: M L Rothenberg; J K Benedetti; J S Macdonald; T E Seay; M A Neubauer; C S George; M S Tanaka; J K Giguere; B T Pruitt; J L Abbruzzese Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Joseph C Harris; Andrew D Gilliam; Andrew J McKenzie; Sean A Evans; Anna M Grabowska; Philip A Clarke; Daniel F McWilliams; Sue A Watson Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701
Authors: Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: Henry Q Xiong; Arthur Rosenberg; Albert LoBuglio; William Schmidt; Robert A Wolff; John Deutsch; Michael Needle; James L Abbruzzese Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee Journal: J Exp Med Date: 2004-08-02 Impact factor: 14.307
Authors: H Ulrich-Pur; M Raderer; G Verena Kornek; B Schüll; K Schmid; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; W Scheithauer Journal: Br J Cancer Date: 2003-04-22 Impact factor: 7.640
Authors: Dung T Le; Dirk G Brockstedt; Ran Nir-Paz; Johannes Hampl; Shruti Mathur; John Nemunaitis; Daniel H Sterman; Raffit Hassan; Eric Lutz; Bentley Moyer; Martin Giedlin; Jana-Lynn Louis; Elizabeth A Sugar; Alice Pons; Andrea L Cox; Jordana Levine; Aimee Luck Murphy; Peter Illei; Thomas W Dubensky; Joseph E Eiden; Elizabeth M Jaffee; Daniel A Laheru Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong Journal: Cell Immunol Date: 2010-03-06 Impact factor: 4.868
Authors: Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox Journal: Cancer J Date: 2011 Sep-Oct Impact factor: 3.360
Authors: Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg Journal: Immunol Rev Date: 2014-01 Impact factor: 12.988
Authors: Aaron J Schueneman; Elizabeth A Sugar; Jennifer Uram; Elaine Bigelow; Joseph M Herman; Barish H Edil; Elizabeth M Jaffee; Lei Zheng; Daniel A Laheru Journal: Ann Surg Oncol Date: 2013-09-18 Impact factor: 5.344